×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
EGRX – eagle pharmaceuticals, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
EGRX
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
11/21
03:09 am
egrx
Eagle Pharmaceuticals, Inc. (NASDAQ: EGRX) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.
Neutral
Report
Eagle Pharmaceuticals, Inc. (NASDAQ: EGRX) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.
11/15
05:15 pm
egrx
Eagle Announces Update on Delisting from Nasdaq and SEC Deregistration [Yahoo! Finance]
High
Report
Eagle Announces Update on Delisting from Nasdaq and SEC Deregistration [Yahoo! Finance]
11/15
05:00 pm
egrx
Eagle Announces Update on Delisting from Nasdaq and SEC Deregistration
High
Report
Eagle Announces Update on Delisting from Nasdaq and SEC Deregistration
11/13
03:01 am
egrx
Eagle Pharmaceuticals, Inc. (NASDAQ: EGRX) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.
High
Report
Eagle Pharmaceuticals, Inc. (NASDAQ: EGRX) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.
11/12
07:00 am
egrx
Eagle Pharmaceuticals Appoints Christopher Krawtschuk as Chief Financial Officer
Medium
Report
Eagle Pharmaceuticals Appoints Christopher Krawtschuk as Chief Financial Officer
11/5
02:15 am
egrx
Eagle Pharmaceuticals, Inc. (NASDAQ: EGRX) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.
High
Report
Eagle Pharmaceuticals, Inc. (NASDAQ: EGRX) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.
10/12
02:04 am
egrx
Eagle Pharmaceuticals, Inc. (NASDAQ: EGRX) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.
High
Report
Eagle Pharmaceuticals, Inc. (NASDAQ: EGRX) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.
10/4
02:12 am
egrx
Eagle Pharmaceuticals, Inc. (NASDAQ: EGRX) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.
High
Report
Eagle Pharmaceuticals, Inc. (NASDAQ: EGRX) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
11/19
08:00 pm
egrx
Form 3 EAGLE PHARMACEUTICALS, For: Nov 11 Filed by: Krawtschuk Christopher
Low
Report
Form 3 EAGLE PHARMACEUTICALS, For: Nov 11 Filed by: Krawtschuk Christopher
11/15
05:20 pm
egrx
Form 8-K EAGLE PHARMACEUTICALS, For: Nov 15
High
Report
Form 8-K EAGLE PHARMACEUTICALS, For: Nov 15
11/14
11:35 am
egrx
Form SC 13G/A EAGLE PHARMACEUTICALS, Filed by: BRANDES INVESTMENT PARTNERS, LP
Medium
Report
Form SC 13G/A EAGLE PHARMACEUTICALS, Filed by: BRANDES INVESTMENT PARTNERS, LP
11/14
10:25 am
egrx
Form SC 13G/A EAGLE PHARMACEUTICALS, Filed by: JANUS HENDERSON GROUP PLC
Medium
Report
Form SC 13G/A EAGLE PHARMACEUTICALS, Filed by: JANUS HENDERSON GROUP PLC
11/13
08:31 am
egrx
Form NT 10-Q EAGLE PHARMACEUTICALS, For: Sep 30
High
Report
Form NT 10-Q EAGLE PHARMACEUTICALS, For: Sep 30
11/12
01:25 pm
egrx
Form SC 13G EAGLE PHARMACEUTICALS, Filed by: CITIGROUP INC
High
Report
Form SC 13G EAGLE PHARMACEUTICALS, Filed by: CITIGROUP INC
11/12
09:22 am
egrx
Form 8-K EAGLE PHARMACEUTICALS, For: Nov 08
Medium
Report
Form 8-K EAGLE PHARMACEUTICALS, For: Nov 08
11/5
04:32 pm
egrx
Form SC 13G/A EAGLE PHARMACEUTICALS, Filed by: Nantahala Capital Management, LLC
Neutral
Report
Form SC 13G/A EAGLE PHARMACEUTICALS, Filed by: Nantahala Capital Management, LLC
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
3/30
Eagle Pharmaceuticals’ Japanese Licensing Partner SymBio Announces Completion of Clinical Trial Enrollment for TREAKISYM® Rapid Infusion Liquid Bendamustine Formulation
12.9%
4/16 Eagle Pharmaceuticals Announces Laboratory Test Results Demonstrating In Vitro Antiviral Activity of RYANODEX® (dantrolene sodium) Against Coronavirus SARS-CoV-2 7.6%
5/7 Q1/2019 3/31/2019 EPS 1.010 ZacksConsensus 0.210 ActVsEst 0.800 - Beat 6.9%
3/2 Form 10-K EAGLE PHARMACEUTICALS, For: Dec 31 6.3%
3/17 Form 8-K EAGLE PHARMACEUTICALS, For: Mar 17 5.3%
12/10 Form 8-K EAGLE PHARMACEUTICALS, For: Dec 04 4.3%
6/4 Form 8-K EAGLE PHARMACEUTICALS, For: Jun 04 3.9%
8/8 Q2/2019 6/30/2019 EPS 0.840 ZacksConsensus 0.310 ActVsEst 0.530 - Beat 3.3%
7/3 Eagle Pharmaceuticals Inc (NASDAQ: EGRX) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $63.00 price target on the stock. 3.2%
1/13 Tyme Technologies: Why Investors Should Be Bullish On The Eagle Partnership [Seeking Alpha] 2.9%
4/16 Eagle Pharmaceuticals Announces Laboratory Test Results Demonstrating In Vitro Antiviral Activity of RYANODEX® (dantrolene sodium) Against Coronavirus SARS-CoV-2 7.6%
5/7 Q1/2019 3/31/2019 EPS 1.010 ZacksConsensus 0.210 ActVsEst 0.800 - Beat 6.9%
3/2 Form 10-K EAGLE PHARMACEUTICALS, For: Dec 31 6.3%
3/17 Form 8-K EAGLE PHARMACEUTICALS, For: Mar 17 5.3%
12/10 Form 8-K EAGLE PHARMACEUTICALS, For: Dec 04 4.3%
6/4 Form 8-K EAGLE PHARMACEUTICALS, For: Jun 04 3.9%
8/8 Q2/2019 6/30/2019 EPS 0.840 ZacksConsensus 0.310 ActVsEst 0.530 - Beat 3.3%
7/3 Eagle Pharmaceuticals Inc (NASDAQ: EGRX) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $63.00 price target on the stock. 3.2%
1/13 Tyme Technologies: Why Investors Should Be Bullish On The Eagle Partnership [Seeking Alpha] 2.9%
TOP News Decliners
4/28
Court Issues Favorable Patent Litigation Decision for Eagle Pharmaceuticals, Inc. and Teva Pharmaceutical Industries Ltd. for BENDEKA (bendamustine hydrochloride injection)
-10.4%
3/6 Eagle Pharmaceuticals Inc (NASDAQ: EGRX) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "strong sell" rating. -8.3%
3/2 Eagle Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Results -8.1%
4/21 Eagle Pharmaceuticals Inc (NASDAQ: EGRX) had its "hold" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $46.00 price target on the stock. -7.2%
3/16 Form 8-K EAGLE PHARMACEUTICALS, For: Mar 13 -6.0%
11/12 Form 8-K EAGLE PHARMACEUTICALS, For: Nov 12 -5.6%
4/29 Eagle Pharmaceuticals to Discuss First Quarter 2020 Financial Results on May 11, 2020 -5.1%
5/22 Form 8-K EAGLE PHARMACEUTICALS, For: May 22 -4.7%
1/7 Form 8-K EAGLE PHARMACEUTICALS, For: Jan 07 -4.4%
6/21 Form 8-K EAGLE PHARMACEUTICALS, For: Jun 21 -3.6%
3/6 Eagle Pharmaceuticals Inc (NASDAQ: EGRX) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "strong sell" rating. -8.3%
3/2 Eagle Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Results -8.1%
4/21 Eagle Pharmaceuticals Inc (NASDAQ: EGRX) had its "hold" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $46.00 price target on the stock. -7.2%
3/16 Form 8-K EAGLE PHARMACEUTICALS, For: Mar 13 -6.0%
11/12 Form 8-K EAGLE PHARMACEUTICALS, For: Nov 12 -5.6%
4/29 Eagle Pharmaceuticals to Discuss First Quarter 2020 Financial Results on May 11, 2020 -5.1%
5/22 Form 8-K EAGLE PHARMACEUTICALS, For: May 22 -4.7%
1/7 Form 8-K EAGLE PHARMACEUTICALS, For: Jan 07 -4.4%
6/21 Form 8-K EAGLE PHARMACEUTICALS, For: Jun 21 -3.6%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: